Visit https://www.peervoice.com/RNT860 to view the entire programme with slides. After completing “David Jones, OBE, MD, PhD - New Options and Opportunities for Personalised Treatment of Primary Biliary Cholangitis: Have You Updated Your Approach?”, participants will be able to: Describe the contemporary approach to pharmacologic treatment of primary biliary cholangitis (PBC); Identify individuals with PBC who may benefit from initiation of second-line treatment options or a transition in second-line treatment approach; and Apply available data to guide the personalisation of second-line treatment choice for individuals with PBC based on person- and disease-specific characteristics (eg, presence of moderate-to-severe pruritus or compensated cirrhosis, prior treatment with fibrates or obeticholic acid [OCA]).

Visit https://www.peervoice.com/NUF860 to view the entire programme with slides. After completing “Eva Diehl - Wiesenecker, MD - Rare Causes of Abdominal Pain: Differential Diagnosis of Uncommon but Diagnosable Causes in the Emergency Room”, participants will be able to: Discuss the impact of delayed and/or misdiagnosis of a rare cause of abdominal pain on patients and healthcare systems; Recognise the clinical features that would increase suspicion of a rare cause of abdominal pain; and Apply appropriate diagnostic algorithms for patients who present to the emergency room with severe abdominal pain and in whom the findings from a typical work-up are inconclusive.

Visit https://www.peervoice.com/STJ860 to view the entire programme with slides. After completing “Christie M. Ballantyne, MD - At the Forefront of the Latest Developments in FCS: Expert Perspectives on Emerging Evidence”, participants will be able to: Improved knowledge of current efficacy data from clinical trials of novel treatments for familial chylomicronemia syndrome (FCS); and Improved knowledge of the safety profiles of emerging treatments for FCS, based on clinical trial outcomes.

Visit https://www.peervoice.com/EAW860 to view the entire programme with slides. After completing “Martin Metz, MD - Bringing Chronic Spontaneous Urticaria Under Control: Available and Anticipated Strategies for Escalating Treatment”, participants will be able to: Recognise unmet needs and burdens experienced by patients living with inadequately controlled chronic spontaneous urticaria (CSU); Provide appropriate, individualised treatment to patients with CSU whose symptoms are inadequately controlled with second-generation H1-antihistamines; and Assess the clinical significance of clinical trial data evaluating the safety and efficacy of novel treatment approaches (such as BTK inhibitors) in the management of CSU.

Visit https://www.peervoice.com/UYE860 to view the entire programme with slides. After completing “Angela Kay Fitch, MD, FACP, MFOMA - Separating Signal From Noise: Overcoming the Challenges of Obesity Management in Real-World Clinical Practice”, participants will be able to: Describe the key components involved in maintaining food intake homeostasis and how these influence appetite and eating behaviour in obesity; Appraise the evidence surrounding phenotype-guided approaches to obesity management; Implement practical, culturally competent strategies to overcome barriers to optimal obesity care and address unmet needs amongst patients in the Black community; and Utilise practical approaches that consider obesity phenotype and concomitant diseases, including depression, to establish sustainable individualised treatment strategies in the management of obesity.

Visit https://www.peervoice.com/BAN860 to view the entire programme with slides. After completing “Emma Guttman-Yassky, MD, PhD - Atopic Dermatitis and the 0X40 Pathway: Understanding the Therapeutic Potential of OX40 Inhibition in Atopic Dermatitis”, participants will be able to: Explain the mechanistic rationale for OX40 pathway inhibitors in atopic dermatitis (AD); Describe the benefits and limitations of current disease management strategies in AD; and Use clinical data to evaluate the effects of emerging OX40 inhibitors for patients with AD in the context of current clinical management.

Visit https://www.peervoice.com/HAR860 to view the entire programme with slides. After completing “Richard David Graham Leslie, MD, FRCP, FAoP - When Could Dysglycaemia in Adults Be Type 1 Diabetes? Expert Perspectives on Recognising and Addressing Diagnostic Complexities and Challenges”, participants will be able to: Evaluate epidemiological evidence on the incidence of misclassification of type 1 diabetes in adults as type 2 diabetes; Recognise differential diagnoses of type 1 diabetes in adults; and Identify patients who are receiving treatment for type 2 diabetes who have clinical features of type 1 diabetes and should undergo further diagnostic testing.

Visit https://www.peervoice.com/CCB860 to view the entire programme with slides. After completing “Francesco Lapi, PharmD, PhD - Chronic, Painful, and Often Overlooked: Working Together to Optimise Outcomes in Hidradenitis Suppurativa”, participants will be able to: Recognise barriers to optimal care faced by patients with hidradenitis suppurativa (HS), including delays in diagnosis and therapeutic area; Recall the results of clinical trials and real-world studies assessing short- and long-term outcomes associated with the use of biologic therapies in the management of HS; and Formulate appropriate, individualised treatment plans for patients with HS based on their goals of therapy, type and severity of HS, and present comorbidities.

Visit https://www.peervoice.com/WWZ860 to view the entire programme with slides. After completing “Kris V. Kowdley, MD - Advancing Individualized Treatment Strategies in Patients With Primary Biliary Cholangitis”, participants will be able to: Outline the role of patient perspectives of disease burden in making shared decisions about treatment selection in primary biliary cholangitis (PBC); Summarize the clinical data pertaining to current and emerging first- and second-line therapies used in the management of patients with PBC; Utilize guideline recommendations for evaluation of symptoms and response to therapy in patients with PBC; and Use individualized evidence-based treatment strategies that incorporate the perspectives of patients with PBC.

Visit https://www.peervoice.com/EBC860 to view the entire programme with slides. After completing “Kevin Fernando, MBChB, BSC Hons (Med Sci), MSc Diabetes - The Many Faces of PBC: Recognising Opportunities to Optimise Identification and Intervention Across Diverse Patient Populations”, participants will be able to: Explain the rationale for timely diagnosis and optimised treatment of people living with primary biliary cholangitis (PBC); Recognise current gaps in the identification and treatment of PBC, including differences based on factors such as gender, race, age, and geography; and Apply evidence-based approaches to the diagnosis and management of PBC to address unmet needs across diverse patient population.

Visit https://www.peervoice.com/CNZ860 to view the entire programme with slides. After completing “Gregory Y. H. Lip, MD - Optimising Oral Anticoagulant Use in Atrial Fibrillation: The Role of Real-World Evidence in Informing, Individualising, and Improving Care”, participants will be able to: Recognise the role, strengths, and limitations of real-world evidence in guiding decision-making related to stroke prevention in patients with atrial fibrillation (AF); Evaluate available real-world data studies related to the use of oral anticoagulants for stroke prevention in AF, including in special populations; and Propose patient-specific oral anticoagulation plans for stroke prevention in AF based on not only clinical trials, but also real-world evidence.

Visit https://www.peervoice.com/GTU860 to view the entire programme with slides. After completing “Olga Kordonouri, MD - Confronting the Silent Progression of Type 1 Diabetes: Rationales and Roadmaps for Early Detection and Proactive Intervention”, participants will be able to: Explain the rationale for conducting autoantibody screening for presymptomatic type 1 diabetes (T1D); Identify current recommendations and practical considerations for conducting autoantibody screening for T1D; Use the results of autoantibody screening for T1D to inform education, monitoring, follow-up, and management plans for individual patients; and Evaluate the mechanisms of, available efficacy and safety data for, and practical considerations related to novel therapies targeting the underlying pathogenesis of T1D.

Visit https://www.peervoice.com/BYM860 to view the entire programme with slides. After completing “Gideon Hirschfield, MB BChir, FRCP, PhD - Keeping Pace With the Latest in PBC: Practical Perspectives on What’s New and What’s Next”, participants will be able to: Differentiate between available and emerging therapies for the treatment of primary biliary cholangitis (PBC); Evaluate available efficacy and safety data for emerging therapies for the treatment of PBC; and Define key practical steps in the identification of patients who may benefit from additional lines of treatment for PBC.

Visit https://www.peervoice.com/RAB860 to view the entire programme with slides. After completing “Ian SD Roberts, MBChB, FRCPath / Joris Roelofs, MD, PhD - Best Practices in Renal Pathology: Avoiding Common Pitfalls in the Diagnostic Pathways for Glomerular Diseases”, participants will be able to: Identify the importance of histopathologic findings in differentiating between specific glomerular diseases; Apply best practices in the preparation and evaluation of renal biopsies for specific glomerular diseases such as complement 3 glomerulopathy (C3G), immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN), and immunoglobulin A nephropathy (IgAN); Propose practical strategies for communication and reporting which facilitate collaboration between nephropathologists and nephrologists to achieve clinical-pathologic correlation and definitive diagnosis of specific glomerular diseases; and Evaluate novel processes for, and benefits of, digitisation and archiving of renal biopsy samples.

Visit https://www.peervoice.com/DNW860 to view the entire programme with slides. After completing “Kris V. Kowdley, MD - Navigating Cases of PBC Alongside the Experts: Best Practices in Tracking Treatment Response and Targeting Contemporary Goals of Care”, participants will be able to: Propose goals of treatment in primary biliary cholangitis (PBC) related to both disease and symptom control; Apply recommended approaches to evaluate patient response to, and tolerance of, first-line treatment for PBC; and Identify patients who may benefit from second-line treatments for PBC.

Visit https://www.peervoice.com/NAU860 to view the entire programme with slides. After completing “Jonathan Barratt, PhD, FRCP / Joris Roelofs, MD, PhD - The Central Role of Renal Pathology in the Differential Diagnosis of Glomerular Diseases: Sharing Expertise, Experience, and Essential Next Steps”, participants will be able to: Explain the pathophysiologic pathways underlying the development of rare kidney diseases, including glomerular diseases such as complement 3 glomerulopathy (C3G), immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN), and immunoglobulin A nephropathy (IgAN); Identify best practices in the evaluation of renal biopsies in the setting of suspected glomerular diseases, including C3G, IC-MPGN, and IgAN; and Design diagnostic workflows for glomerular diseases which facilitate communication and collaboration between nephrologists and nephropathologists to promote definitive diagnosis.

Visit https://www.peervoice.com/GPM860 to view the entire programme with slides. After completing “Jonathan Barratt, PhD, FRCP - Redefining Hope: The IgA Nephropathy Journey”, participants will be able to: Summarize the patient perspective of disease burden and unmet needs in the management of immunoglobulin A nephropathy (IgAN); Recognize the clinical significance of established clinical trial endpoints including estimated glomerular filtration rate (eGFR); and Conceptualize the current and emerging therapeutic developments in terms of the challenges they aim to address in the management of IgAN.

Visit https://www.peervoice.com/VYS860 to view the entire programme with slides. After completing “Angela Fitch, MD, FACP, MFOMA - This Cannot Weight: A Specialist Guide to Weight Management and Obesity Associated With Emotional Eating Behaviours”, participants will be able to: Describe the current patient- and healthcare-associated barriers to accessing obesity management therapy; Summarise the obesity phenotypes including hedonic eating behaviours and their role within the understanding of obesity management; Outline the role and clinical evidence for current therapies used as part of weight management strategies across obesity phenotypes; and Apply evidence-based therapeutic strategies to individualise care in patients with obesity associated with emotional eating.

Visit https://www.peervoice.com/GBR860 to view the entire programme with slides. After completing “Maria Craig, MBBS, PhD, FRACP, MMed(ClinEpid) - Treating T2D in People of Younger Age in This Day and Age: How Would You Manage These Children and Adolescents With T2D?”, participants will be able to: Evaluate the efficacy and safety evidence for recommended interventions to manage type 2 diabetes (T2D) in children and adolescents; Describe age-, disease-, and treatment-related considerations which impact decision-making in the treatment of T2D in children and adolescents; and Propose evidence-based, guideline-recommended management plans for children and adolescents with T2D.

Visit https://www.peervoice.com/QKR860 to view the entire programme with slides. After completing “Fatos Pinar Topsever, MD / Jennifer Green, MD - CGA - Identify and Intervene: Optimising Care Pathways for Chronic Kidney Disease in Patients With Type 2 Diabetes”, participants will be able to: Use recommended screening tests to identify chronic kidney disease (CKD) in patients with type 2 diabetes mellitus (T2DM); Evaluate current efficacy and safety evidence guiding the use of novel treatments for CKD in T2DM; and Apply best practices for the initiation and management of novel therapies for treatment of CKD and T2DM.